VERTEX PHARMACEUTICALS INC / MA (VRTX) Operating margin 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) operating margin by fiscal year — reported operating income divided by reported revenue.
34.8%FY2025 · since FY2016: 0.6% → 34.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 34.8% | +36.9 pp |
| FY2024 | -2.1% | -40.9 pp |
| FY2023 | 38.8% | -9.4 pp |
| FY2022 | 48.2% | +11.5 pp |
| FY2021 | 36.7% | -9.3 pp |
| FY2020 | 46.0% | +17.3 pp |
| FY2019 | 28.8% | +7.9 pp |
| FY2018 | 20.8% | +15.9 pp |
| FY2017 | 5.0% | +4.4 pp |
| FY2016 | 0.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Gross marginVRTX Operating incomeVRTX Operating cash flowVRTX Free cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →